Antiinflammatory actions of glucagon-like peptide-1-based therapies beyond metabolic benefits.
Level 5 - mechanism / opinion, no new human data
Narrative review of preclinical and clinical mechanisms without systematic review methodology or meta-analysis
PubMed 41178710 · doi:10.1172/JCI194751
What was done
This review synthesized preclinical (mouse) and clinical (human) evidence examining the direct and indirect anti-inflammatory actions and underlying biological mechanisms of glucagon-like peptide-1 (GLP-1)-based therapeutics.
What was found
The abstract reports no numerical data. It qualitatively reports that acute and chronic GLP-1 receptor activation lowers systemic and tissue-specific inflammation in mice and humans through both weight loss-dependent and weight loss-independent mechanisms.
Why it matters
It highlights the biological rationale for investigating GLP-1 receptor agonists in non-metabolic inflammatory diseases, such as arthritis, metabolic liver disease, and neurodegenerative disorders.
Limits
This is a narrative review containing no original primary data, quantitative meta-analysis, or systematic study search. Specific effect sizes, cohort sizes, and comparative outcomes are absent from the abstract.
Cited by
- supports GLP-1 receptor agonist drugs reduce systemic inflammation independently of and prior to weight loss.